Impact of HBV therapy on the incidence of hepatocellular carcinoma

Michela Triolo, Cristina Della Corte, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepatitis B virus (HBV) with an annual incidence ranging from 2 to 5%, often independent from the histological stage of underlying liver disease and serological status. Nevertheless, HCC is more often seen in older patients in whom HBV has been asserting its pro-oncogenic properties through both indirect and direct mechanisms. In Europe, HBV-related HCC is associated with cirrhosis in most patients, whereas this is not true in Asia and Africa where the tumour is also common among carriers with mild hepatic fibrosis, probably because of the coexistence of environmental co-carcinogens (aflatoxin) and long standing infection that is often acquired perinatally. Since hepatitis B-related carcinogenesis develops independently of the onset of cirrhosis, antiviral treatments such as nucleo(t)side analogues (NAs) that may result in the regression of fibrosis, prevent clinical decompensation and variceal bleeding, often fail to prevent HCC. Studies enrolling patients treated with lamivudine or rescued with adefovir, i.e. regimens characterized by limited potency and a low to moderate genetic barrier, have clearly been shown to help prevent HCC in patients with chronic hepatitis but not in those with cirrhosis, and in general not in patients that cannot achieve a sustained virological response. More potent anti-HBV drugs, such as entecavir and tenofovir, have been shown to improve the prevention of HCC in responders with cirrhosis, although HCC may still occur even in low risk patients. To attenuate HCC related outcomes, HBV replication must permanently be suppressed and HCC surveillance by abdominal ultrasound should be maintained even in responder patients.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalLiver International
Volume34
Issue numberSUPPL1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Hepatitis B virus
Hepatocellular Carcinoma
Incidence
Fibrosis
Therapeutics
Tenofovir
Environmental Carcinogens
Aflatoxins
Lamivudine
Chronic Hepatitis
Virus Replication
Infection
Hepatitis B
Antiviral Agents
Liver Diseases
Carcinogenesis
Hemorrhage
Liver
Pharmaceutical Preparations

Keywords

  • Hepatitis B virus
  • Hepatocellular carcinoma
  • Interferon-alpha
  • Nucleoside/nucleotide-analogues

ASJC Scopus subject areas

  • Hepatology

Cite this

Impact of HBV therapy on the incidence of hepatocellular carcinoma. / Triolo, Michela; Corte, Cristina Della; Colombo, Massimo.

In: Liver International, Vol. 34, No. SUPPL1, 02.2014, p. 139-145.

Research output: Contribution to journalArticle

Triolo, Michela ; Corte, Cristina Della ; Colombo, Massimo. / Impact of HBV therapy on the incidence of hepatocellular carcinoma. In: Liver International. 2014 ; Vol. 34, No. SUPPL1. pp. 139-145.
@article{c64dd377b823456096649e7a5f1c7352,
title = "Impact of HBV therapy on the incidence of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepatitis B virus (HBV) with an annual incidence ranging from 2 to 5{\%}, often independent from the histological stage of underlying liver disease and serological status. Nevertheless, HCC is more often seen in older patients in whom HBV has been asserting its pro-oncogenic properties through both indirect and direct mechanisms. In Europe, HBV-related HCC is associated with cirrhosis in most patients, whereas this is not true in Asia and Africa where the tumour is also common among carriers with mild hepatic fibrosis, probably because of the coexistence of environmental co-carcinogens (aflatoxin) and long standing infection that is often acquired perinatally. Since hepatitis B-related carcinogenesis develops independently of the onset of cirrhosis, antiviral treatments such as nucleo(t)side analogues (NAs) that may result in the regression of fibrosis, prevent clinical decompensation and variceal bleeding, often fail to prevent HCC. Studies enrolling patients treated with lamivudine or rescued with adefovir, i.e. regimens characterized by limited potency and a low to moderate genetic barrier, have clearly been shown to help prevent HCC in patients with chronic hepatitis but not in those with cirrhosis, and in general not in patients that cannot achieve a sustained virological response. More potent anti-HBV drugs, such as entecavir and tenofovir, have been shown to improve the prevention of HCC in responders with cirrhosis, although HCC may still occur even in low risk patients. To attenuate HCC related outcomes, HBV replication must permanently be suppressed and HCC surveillance by abdominal ultrasound should be maintained even in responder patients.",
keywords = "Hepatitis B virus, Hepatocellular carcinoma, Interferon-alpha, Nucleoside/nucleotide-analogues",
author = "Michela Triolo and Corte, {Cristina Della} and Massimo Colombo",
year = "2014",
month = "2",
doi = "10.1111/liv.12394",
language = "English",
volume = "34",
pages = "139--145",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL1",

}

TY - JOUR

T1 - Impact of HBV therapy on the incidence of hepatocellular carcinoma

AU - Triolo, Michela

AU - Corte, Cristina Della

AU - Colombo, Massimo

PY - 2014/2

Y1 - 2014/2

N2 - Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepatitis B virus (HBV) with an annual incidence ranging from 2 to 5%, often independent from the histological stage of underlying liver disease and serological status. Nevertheless, HCC is more often seen in older patients in whom HBV has been asserting its pro-oncogenic properties through both indirect and direct mechanisms. In Europe, HBV-related HCC is associated with cirrhosis in most patients, whereas this is not true in Asia and Africa where the tumour is also common among carriers with mild hepatic fibrosis, probably because of the coexistence of environmental co-carcinogens (aflatoxin) and long standing infection that is often acquired perinatally. Since hepatitis B-related carcinogenesis develops independently of the onset of cirrhosis, antiviral treatments such as nucleo(t)side analogues (NAs) that may result in the regression of fibrosis, prevent clinical decompensation and variceal bleeding, often fail to prevent HCC. Studies enrolling patients treated with lamivudine or rescued with adefovir, i.e. regimens characterized by limited potency and a low to moderate genetic barrier, have clearly been shown to help prevent HCC in patients with chronic hepatitis but not in those with cirrhosis, and in general not in patients that cannot achieve a sustained virological response. More potent anti-HBV drugs, such as entecavir and tenofovir, have been shown to improve the prevention of HCC in responders with cirrhosis, although HCC may still occur even in low risk patients. To attenuate HCC related outcomes, HBV replication must permanently be suppressed and HCC surveillance by abdominal ultrasound should be maintained even in responder patients.

AB - Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepatitis B virus (HBV) with an annual incidence ranging from 2 to 5%, often independent from the histological stage of underlying liver disease and serological status. Nevertheless, HCC is more often seen in older patients in whom HBV has been asserting its pro-oncogenic properties through both indirect and direct mechanisms. In Europe, HBV-related HCC is associated with cirrhosis in most patients, whereas this is not true in Asia and Africa where the tumour is also common among carriers with mild hepatic fibrosis, probably because of the coexistence of environmental co-carcinogens (aflatoxin) and long standing infection that is often acquired perinatally. Since hepatitis B-related carcinogenesis develops independently of the onset of cirrhosis, antiviral treatments such as nucleo(t)side analogues (NAs) that may result in the regression of fibrosis, prevent clinical decompensation and variceal bleeding, often fail to prevent HCC. Studies enrolling patients treated with lamivudine or rescued with adefovir, i.e. regimens characterized by limited potency and a low to moderate genetic barrier, have clearly been shown to help prevent HCC in patients with chronic hepatitis but not in those with cirrhosis, and in general not in patients that cannot achieve a sustained virological response. More potent anti-HBV drugs, such as entecavir and tenofovir, have been shown to improve the prevention of HCC in responders with cirrhosis, although HCC may still occur even in low risk patients. To attenuate HCC related outcomes, HBV replication must permanently be suppressed and HCC surveillance by abdominal ultrasound should be maintained even in responder patients.

KW - Hepatitis B virus

KW - Hepatocellular carcinoma

KW - Interferon-alpha

KW - Nucleoside/nucleotide-analogues

UR - http://www.scopus.com/inward/record.url?scp=84890880978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890880978&partnerID=8YFLogxK

U2 - 10.1111/liv.12394

DO - 10.1111/liv.12394

M3 - Article

C2 - 24373091

AN - SCOPUS:84890880978

VL - 34

SP - 139

EP - 145

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL1

ER -